China's HeartCare Medical H1 revenue surges on stroke segment growth

Shanghai HeartCare Medical Technology

31/08/2026 10:14

Overview
China medical device maker's H1 revenue rose 56.9% yr/yr to RMB291 mln
Net profit attributable to shareholders grew 18.5% yr/yr to RMB60.4 mln
Company cites product recognition and demand as key drivers for growth

Outlook
Company expects CE certification for Embolic Coil System in Q3 2026
Clinical enrolment for Carotid Artery Stent expected to complete within 2026

Result Drivers
PRODUCT ADOPTION - Co said expanded hospital adoption and upgrades to ischemic stroke products, including Aspiration Catheter, drove steady growth in sales
HEMORRHAGIC STROKE SEGMENT - Co said hemorrhagic stroke business was fastest-growing, with Vascular Reconstruction Device and Embolic Coil System sales volumes rising sharply
OPERATIONAL EFFICIENCY - Co said digitalization, AI deployment and lean production initiatives improved efficiency and lifted gross margin

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 291 mln
 
H1 Profit and total comprehensive income for
the period
 
RMB 60.40 mln
 

Reuters Recommended Reads
Aug 28 - China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Aug 28 - China's Zhaoke Ophthalmology H1 revenue rises
Aug 28 - Chinese traditional medicine maker Tong Ren Tang profit falls on weaker demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-31/69c70df7-68a3-457f-9820-37efd1596869.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)